Published on November 20, 2026
Diakonos Oncology, a Brain Tumor Investment Fund™ portfolio company, presented clinical data on its investigational dendritic cell immunotherapy DOC1021 (dubodencel) at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia. The company analyzed 20 patients with newly diagnosed, MGMT-unmethylated glioblastoma (GBM) from its phase 1 trial and expanded access protocol. In this exploratory analysis, median overall survival was 18.5 months, compared with 14.5 to 14.9 months in three published standard-of-care control arms. That comparison is unadjusted and uses historical controls. No dose-limiting toxicities were seen across four dose levels, and most adverse events were grade 1 or 2.
DOC1021 is made from each patient’s own dendritic cells, which are loaded with both lysate and amplified mRNA from the patient’s tumor. It requires no genetic engineering, lymphodepleting chemotherapy, or high-dose IL-2, and it can be given as an outpatient treatment. The randomized, multicenter phase 2 DOC-GBM2 trial (NCT06805305) compares DOC1021 plus standard of care with standard of care alone in IDH-wildtype newly diagnosed GBM. It has enrolled 100 patients and passed a prespecified interim futility analysis. DOC1021 holds FDA Fast Track and Orphan Drug designations in GBM.
Read Diakonos Oncology’s full announcement: Diakonos Oncology presents DOC1021 data at SNO 2026 →
BTIF is not responsible for the content of third-party press releases.